Bartolomeo AC, Morris H, Buccafusco JJ, Kille N, Rosenzweig-Lipson S, Husbands MG, Sabb AL, Abou-Gharbia M, Moyer JA, Boast CA (2000)
The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist
Journal of Pharmacology & Experimental Therapeutics 292: 584

Sabb AL, Husbands MG, Tokolics J, Stein RP, Tasse RP, Boast CA, Moyer JA, Abou-Gharbia M (1999)
Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling
Bioorganic & Medicinal Chemistry Lett 9: 1895

Bartolomeo AC, Morris H, Boast CA (1997)
Arecoline via miniosmotic pump improves AF64A-impaired radial maze performance in rats: a possible model of Alzheimer's disease
Neurobiol Learn Mem 68: 333

Maurer SA, Storch FE, LaForge RR, Boast CA (1995)
Task difficulty determines the differential memory-impairing effects of EAA antagonists in gerbils
Pharmacol Biochem Behav 51: 345

Boast CA, Leventer S, Sabb A, Abelson M, Bender R, Giacomo D, Maurer S, McArthur S, Mehta O, Morris H, Moyer J, Storchet F (1991)
Biochemical and behavioral characterization of a novel cholinergic agonist, SR 95639
Pharmacol Biochem Behav 39: 287

Murphy DE, Boast CA (1985)
Searching for models of Alzheimer's disease: a comparison of four amnestic treatments in two behavioral tasks
Annals of the New York Academy of Sciences 444: 450

Boast CA, Bernard PS, Barbaz BS, Bergen KM (1983)
The neuropharmacology of various diazepam antagonists
Neuropharmacology 22: 1511

Fisher SK, Boast CA, Agranoff BW (1980)
The muscarinic stimulation of phospholipid labeling in hippocampus is independent of its cholinergic input
Brain Research 189: 284